PTPN22 and leprosy: An elevated risk of leprosy was perceived in patients with PTPN22-C1858T polymorphism in heterozygote models [CT versus CC: OR = 2.91 (95% CI: 0.99–8.60, PH = 0.094)] and dominant models [TT/CT versus CC: OR = 2.91 (95% CI: 0.99–8.60, PH = 0.094)] (Table 2).